Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Systems analyses of induction and maintenance of immunity to SARS-CoV-2 vaccination in kidney transplant recipients receiving mycophenolate mofetil immunotherapy

Award Number: U01AI179524
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

Systems analyses of induction and maintenance of immunity to SARS-CoV-2 vaccination in kidney transplant recipients receiving mycophenolate mofetil immunotherapy - PROJECT SUMMARY/ABSTRACT Immunocompromised patients, including those requiring immunosuppressive therapy following organ transplantation, are at high risk for severe disease from SARS‐CoV‐2. As SARS-CoV-2 rapidly transitions from a pandemic virus to endemic status, like influenza, seasonal vaccinations against emerging variants will likely become the primary tool for limiting morbidity and mortality. While the efficacy of vaccination against SARS-CoV- 2 has been very promising, specific populations have been identified who are at increased risk of failing to develop protective immunity. Immunocompromised populations respond poorly to SARS-CoV-2 vaccination, particularly solid organ transplant (SOT) recipients receiving immunosuppressive therapy. Within SOT recipients, the type and dose of immunosuppressive therapy have further been shown to impact vaccine efficacy. Patients receiving mycophenolate mofetil (MMF) immunotherapy, which functions by preventing B and T cell proliferation/activation, as well as leukocyte recruitment, have the poorest humoral and cellular response post- vaccination for SARS-CoV-2. Preliminary evidence suggests that discontinuing MMF before vaccination improves humoral responses in SOT recipients. This project will test the hypothesis that coordinated innate and adaptive dysregulation pre-vaccination driven by MMF immunosuppressive therapy diminishes the quality, quantity, and durability of cellular and humoral immunity to SARS-CoV-2 in kidney transplant recipients. In Aim 1, we will characterize the impact of MMF on the generation, quality, and maintenance of adaptive immune responses to SARS-CoV-2 vaccination in SOT recipients. We will use validated assays to quantify and functionally profile humoral and cellular immunity to SARS-CoV-2. In Aim 2, we will define the pre-vaccine immunological determinants of a protective host immune response to SARS-CoV-2 vaccination in kidney transplant recipients and identify the mechanisms of MMF-diminished immunity. We will use systems biological tools to comprehensively profile, at the single-cell level, the peripheral immune system prior to vaccination. In Aim 3, we will determine how pre-vaccine MMF reduction impacts the host immune response to SARS-CoV-2 booster vaccination in kidney transplant recipients. Together, these data will provide a comprehensive, mechanistic understanding of how MMF immunotherapy dysregulates the immune system in SOT recipients and how this dysregulation impacts the induction and durability of protective immunity against SARS-CoV-2. This knowledge will allow the development of targeted strategies to correct or circumvent MMF-driven immune dysregulation, thereby permitting efficacious responses to SARS-CoV-2, and other vaccines, in SOT recipients and other at-risk populations.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $678,904 )
2026	2026	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	3	1/28/2026	NON-COMPETING CONTINUATION	$678,904
														Subtotal = $678,904

Issue Date FY: 2025 ( Subtotal = $658,538 )
2025	2025	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	2	2/12/2025	NON-COMPETING CONTINUATION	$658,538
														Subtotal = $658,538

Issue Date FY: 2024 ( Subtotal = $605,731 )
2024	2024	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10920 WILSHIRE BLVD STE 500	LOS ANGELES	CA	90024	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	1	3/1/2024	NEW	$605,731
														Subtotal = $605,731

Grand Total All Awards = $1,943,173

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Systems analyses of induction and maintenance of immunity to SARS-CoV-2 vaccination in kidney transplant recipients receiving mycophenolate mofetil immunotherapy

Award Number: U01AI179524

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer